MedPath

ong-term observational study of Gene Therapy for AADC deficiency

Not Applicable
Recruiting
Conditions
Aromatic L-amino acid decarboxylase deficiency
Registration Number
JPRN-jRCT2033220245
Lead Sponsor
Yamagata Takanori
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
1
Inclusion Criteria

Patients who enrolled in the Phase I/II Study of Gene Therapy for AADC deficiency, and who completed or discontinued the study.
-Female patients who are able to become pregnant, and whose partners agree to use medically effective contraceptive methods throughout the study period.

Exclusion Criteria

-Patients who cannot undergo MRI.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To investigate the long-term tolerability, safety, and efficacy of the study product in patients with AADC deficiency, after intracerebral administrations of AAV-hAADC-2 into the putamen.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath